Research · Randomized controlled trial
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial
What it found
Neither lutein/zeaxanthin nor omega-3 significantly reduced progression in the primary analysis; secondary analyses favoured lutein/zeaxanthin as a substitute for beta-carotene, while omega-3 showed no benefit.
- Design
- Randomized controlled trial
- Year
- 2013
- Sample size
- 4,203
- Population
- adults aged 50–85 at high risk of progression to advanced AMD
- Intervention
- lutein 10 mg + zeaxanthin 2 mg, and/or DHA+EPA, added to the AREDS formula vs placebo
- Outcome
- development of advanced AMD
- Journal
- JAMA
Citation last checked 2026-06-21.